Protox to present benign prostatic hyperplasia data at Canadian Urology Conference

    VANCOUVER, June 29 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader
in the development of receptor targeted fusion proteins, today announced that
data from their open label Phase 2 clinical study of PRX302 in patients with
moderate to severe benign prostatic hyperplasia (BPH), will be presented this
afternoon at the 64th Annual Meeting of the Canadian Urological Association
(CUA). The 2009 CUA Meeting is the country's largest gathering of urology
professionals taking place at the Westin Harbour Castle Hotel in Toronto,
    Dr. Peter Pommerville, M.D., Principal Investigator from the clinical
site at Can-Med Clinical Research Centre in Victoria, B.C., will present the
poster entitled: "PRX302, a PSA-Activated Protoxin, is Well Tolerated and
Induces Symptomatic Relief and Prostate Volume Reduction when Administered
Transperineally to Men with BPH" at 4:30 p.m. Based on the promising results
from this open label Phase 2 study the Company is enrolling patients in a
double-blinded Phase 2 placebo controlled clinical trial called TRIUMPH, with
results expected in the fourth quarter of 2009.

    About PRX302

    PRX302 is the lead drug in the company's PORxin(TM) technology platform.
PORxin drugs are pore-forming pro-drugs that are activated by specific
proteases produced at elevated levels on the surface of target cells. PRX302
has been generated by engineering the naturally occurring toxin proaerolysin
so that it is activated by prostate-specific antigen (PSA), an enzyme that is
overproduced in patients suffering from prostate cancer and BPH. Once
activated, the drug punches holes in the cells causing the contents to leak
out and ultimately cell death.

    About BPH

    BPH is a common urological condition characterized by painful and
bothersome symptoms that include difficulty in initiating a urine stream, a
sense of urgency, dribbling, incomplete emptying of the bladder, waking
several times during the night to urinate and sometimes the presence of blood
in the urine. More than half of all men will have symptoms of BPH by the age
of 60 and as many as 90% may suffer from BPH after the age of 80. Current oral
therapies mainly provide symptomatic relief, may take months before they take
effect and can trigger a range of side effects including sexual dysfunction
and hypotension. It is estimated that in the seven largest global markets
approximately 10 million men are treated annually with oral therapies and
these products encompass approximately U.S. $3 billion of sales each year.
Surgical options, including minimally invasive procedures, can cause sexual
dysfunction, incontinence as well as other more serious procedure-related
effects. Surgical measures can require significant recovery time and may
require catheterization for up to several weeks post-treatment. Nearly 600,000
surgical procedures are conducted annually in the seven largest markets.

    About Protox

    Protox Therapeutics is a leader in advancing novel, receptor targeted
fusion proteins. Two novel drug candidates derived from the company's
INxin(TM) and PORxin(TM) platforms are being developed in three clinical
programs. Protox's lead program, PRX302 (PORxin), is currently being studied
in a Phase 2b placebo controlled trial to treat benign prostatic hyperplasia
(BPH or enlarged prostate). Final positive Phase 2a results treating BPH
patients were released at the end of 2008 and a phase 2a clinical trial
evaluating PRX302 for the treatment of localized prostate cancer is ongoing. A
Phase 2a clinical trial evaluating PRX321 (INxin) for the treatment of primary
brain cancer has been completed and the drug has received Fast Track
Designation and Orphan Drug Status from the US FDA and EMEA. Protox is also
collaborating with the U.S. National Institutes of Health (NIH) on a research
program focused on the discovery of next generation fully human targeted

    Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Protox'
current beliefs as well as assumptions made by and information currently
available to Protox and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Protox in its public securities filings; actual
events may differ materially from current expectations. Protox disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

For further information:

For further information: James Beesley, Senior Director, Investor
Relations, Protox Therapeutics, (604) 484-0975,; Michael Moore, Investor Relations, Equicom
Group, (416) 815-0700 x 241,

Organization Profile

Sophiris Bio, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890